



MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan 06, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 28th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2010 at 9:00 a.m. PT in San Francisco.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at <http://www.mappharma.com>. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at <http://www.mappharma.com>.

CONTACT:

Lisa Borland
MAP Pharmaceuticals, Inc.
(650) 386-3122

SOURCE MAP Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved